^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

centanamycin (AS-1-145)

i
Other names: AS-1-145, D716970, ML-970, NSC 716970
Associations
Trials
Company:
AstraZeneca
Drug class:
DNA cross linking agent
Associations
Trials
over4years
[VIRTUAL] Resveratrol can miss laryngeal squamous cell carcinoma cells from immune response (ESHG 2020)
As a result of the study, gene expression relative change levels for EGFR, MYC, and PD-L1 were determined as 1.145, 0.475, 2.695, respectively. According to these results, resveratrol did not cause a significant change in EGFR and MYC expression levels in the LSCC cell line, while it significantly increased PD-L1 levels. It has been found interesting because the resveratrol, which is normally included in the literature as an anticancer, increases levels of PD-L1 because it is likely to support escape from the immune response.
PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • MYC (V-myc avian myelocytomatosis viral oncogene homolog)
|
PD-L1 expression • EGFR expression • MYC expression
|
centanamycin (AS-1-145)